William O. Hahn

Infectious Disease
325 9th Ave
Seattle, WA 98104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

The sooner you boost the better.

The sooner you boost the better.

Journal: Nature immunology
Published: June 23, 2026

A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.

A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.

Journal: medRxiv : the preprint server for health sciences
Published: June 05, 2026

Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.

Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.

Journal: medRxiv : the preprint server for health sciences
Published: May 18, 2026

Induction of multiple HIV-1 neutralizing B Cell Precursors in Humans.

Induction of multiple HIV-1 neutralizing B Cell Precursors in Humans.

Journal: medRxiv : the preprint server for health sciences
Published: May 18, 2026

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).

Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).

Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026

Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort.

Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort.

Journal: Frontiers in immunology
Published: October 10, 2025

DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein.

DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein.

Journal: Vaccine
Published: August 14, 2025

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.

Journal: Science translational medicine
Published: July 30, 2025

Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.

Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.

Journal: Clinical trials (London, England)
Published: July 05, 2025

Innovation in active and passive immunisation of people who are immunocompromised: a call to action.

Innovation in active and passive immunisation of people who are immunocompromised: a call to action.

Journal: The Lancet. Infectious diseases
Published: February 26, 2025

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Viral variant but not host factors associate with SARS-CoV-2 viral kinetics.

Journal: Communications medicine
Published: February 14, 2025
Showing 1-12 of 32

Last Updated: 09/26/2026